Press Releases
November 14, 2024
FDA Expands the Age Indication for Nerivio® as the First-and-Only REN Wearable for Migraine Treatment for Children Aged Eight and Above
Children aged eight and up now have a prescribed non-drug option to treat migraine early and potentially prevent long-term disability and disease progression, addressing a critical unmet need in pediatric migraine care.
Read more
October 1, 2024
More States Join the Movement: The Nerivio® REN Wearable Now Covered by Arizona, New Jersey, Ohio, and Virginia Medicaid Programs
Following Colorado and Washington D.C., this expansion brings an additional seven million people into a new era of accessible and affordable non-drug migraine treatment.
Read more
July 25, 2024
New Study Evaluates Use of the Nerivio® REN Wearable for Treatment of Migraine in Children Under the Age of 12
Nerivio, currently indicated for use in ages 12 and older, demonstrates study results in younger children with migraine.
Read more
July 10, 2024
Colorado Medicaid’s Decision to Cover the Nerivio® REN Wearable Expands Access for Nearly Two Million Americans to Drug-Free, Dual Use Migraine Treatment
Colorado Medicaid is the third federally-funded insurance plan to recognize the REN wearable as safe, effective migraine relief for adolescents and adults ages 12 years and older
Read more
May 21, 2024
DC Medicaid Becomes the First Medicaid Plan to Cover the Nerivio® REN Wearable, a Non-Drug Treatment for Migraine
This represents the second federally funded insurance plan, after the Veteran Administration (VA), to cover the innovative therapy
Read more
February 20, 2024
Theranica’s REN Wearable Becomes the First Ever Non-Pharmacological Migraine Treatment to Receive Commercial Coverage in the USA
Highmark Inc. Publishes Commercial Coverage Policy for Nerivio®,a Drug-Free, Dual Use Treatment for Adolescents and Adults Living with Migraine
Read More
December 19, 2023
2023 Marks a Year of Phenomenal Progress for Theranica in Adolescent Migraine Care
Its Leading REN Wearable Device Brings Hope to Adolescents in the Fight Against a Leading Neurologic Disease
Read More
November 28, 2023
New Study Found Preventive Impact in Adolescents Who Frequently Used Nerivio® for Abortive Treatment of Migraine
New Frontiers in Pain Research Study Demonstrates a Reduction in Migraine Days in Teenagers Using the REN Wearable
Read More
November 14, 2023
Theranica Enters Into Agreement With Dr. Reddy’s for Commercializing Nerivio® in Europe
Commercial Collaboration Follows News of Nerivio®’s Expanded CE Mark Approval as Novel Non-Drug, Dual-Use Migraine Treatment for Adolescents and Adults
Read More
October 25, 2023
New Study Demonstrates Consistent Positive Long-Term Adherence and Efficacy of Nerivio® for Treatment of Migraine
Advances in Therapy Publishes Study Finding 12-Month Consistency in Utilization and Efficacy of Non-Drug, Non-Disruptive Wearable to Mitigate Migraine Burden
Read More
September 28, 2023
First Migraine Neuroband Addressing Unmet Needs of Adolescents to Debut at 2023 Child Neurology Society Annual Meeting
Theranica to Unveil Groundbreaking New Real-World Data for Nerivio®, a Novel Drug-Free Device for Acute and Preventive Treatment of Migraine
Read More
September 12, 2023
New Study Evaluates How Quickly the Migraine Preventive Impact of Nerivio® Starts
Randomized Placebo-Controlled Study Published in Pain Management Evaluated the Preventive Efficacy of the Non-Drug Wearable As Early As After Two Weeks of Usage
Read More
August 9, 2023
Nerivio® CE mark indication expanded to preventive and acute treatment of migraine for adolescents and adults
The company prepares for bringing the wearable prescribed device to Europe next year
Read More
June 21, 2023
Clinical Study Evaluated Safety of Using Nerivio® for Treating Migraine in Pregnant Women
Controlled Retrospective Study Compared Use of Drug-Free Solution to Standard Care Treatments for Migraine During Pregnancy
Read More
May 16, 2023
Using Nerivio® for Migraine Prevention Results in Significant Clinical and Cost-Saving Benefits for Patients, Insurers, and Employers, According to a New Health Economics Study
Nerivio Can Greatly Reduce Payer Expenses Through Reduction of Migraine Headache Days, Productivity Loss, and Healthcare Utilization Costs
Read More
April 12, 2023
Nerivio® Proven Effective in Real-World Setting as Drug-Free Acute Treatment of Migraine for Adolescents
Pediatric Neurology Publishes Study Demonstrating Value of Remote Electrical Neuromodulation (REN) Wearable for Young Adults with Migraine
Read More
February 28, 2023
Theranica’s Nerivio® Cleared by FDA for Preventive Treatment of Migraine
Novel Prescription Wearable Proven Effective as a Preventive and Acute Treatment for Adolescents and Adults with Migraine
Read More
January 10, 2023
Theranica Enters Into Agreement With Dr. Reddy’s for Commercializing Nerivio® in India
The Theranica and Dr. Reddy’s Laboratories agreement will bring Nerivio to millions of people with migraine in India
Read More
December 12, 2022
Pennsylvania-based Highmark Inc. Joins Theranica’s Coverage with Evidence Program for Nerivio® Drug-Free Migraine Treatment Device
Members Will Receive Access to Theranica’s Prescribed Wearable Device
Read More
October 24, 2022
Point32Health to Pilot Nerivio® Drug-Free Migraine Treatment Device
Theranica’s Evidence-Based Wearable Device will be Offered to Members Covered Under Harvard Pilgrim Health Care and Tufts Health Plan
Read More
October 18, 2022
Theranica Achieves Positive Results in Placebo-Controlled Pivotal Trial of Nerivio® for Preventive Treatment of Migraine
Remote Electrical Neuromodulation (REN) device Nerivio® demonstrates significant superiority over placebo, reduces mean number of migraine days per month when used every other day
Read More
September 19, 2022
New Study Suggests REN Comparable to Standard Care Prescribed Medications for Acute Treatment of Chronic Migraines
Analysis of Clinical Trial Data Shows No Difference in Effectiveness Outcomes Between Use of Remote Electrical Neuromodulation (REN) Device Nerivio® and Tested Medications
Read More
August 29, 2022
Theranica Secures $45 Million Series C Funding Round
Proceeds to Fund U.S. Commercial Expansion of Migraine Treatment Device, Nerivio®. Financing Led by Philadelphia-Based New Rhein Healthcare, Selected Additional Co-Investors to Join Round at Final Closing
Read More
February 16, 2022
Peer-Reviewed Study Shows Positive Impact of Nerivio’s® Guided Imagery, Education and Relaxation (GIER) Feature on Migraine Treatment Response
Peer-Reviewed Study Shows Positive Impact of Nerivio’s® Guided Imagery, Education and Relaxation (GIER) Feature on Migraine Treatment Response
Read More
Jan 19, 2022
Large Real-World Evidence Analysis Provides Comprehensive Evaluation of Nerivio® as an Effective Acute Treatment for Migraine
Largest peer-reviewed real-world study of a migraine device demonstrates that remote electrical neuromodulation (REN) provides a safe and effective drug-free acute treatment option for migraine sufferers
Read More
December 15, 2021
Healthcare Industry Leader Scott Serota Joins Theranica Board of Directors
Former President and CEO of the Blue Cross Blue Shield Association, Serota Brings Decades of Experience in US Healthcare Leadership
Read More
October 18, 2021
Peer-Reviewed Published Study Provides Further Evidence for the Safety and Efficacy of Nerivio® in Patients with Chronic Migraine
Study shows remote electrical neuromodulation (REN) treatment provides relief for migraine headaches, offering a drug-free acute treatment option for people with chronic migraine
Read More
October 4, 2021
MC-Rx Formalizes Pharmacy Benefit Coverage for Theranica’s Nerivio®, Providing Millions of Covered Members Access to the Novel Drug-Free Migraine Therapeutic
Agreement Simplifies and Accelerates Patient Access to Effective, Low Side Effect Drug Free Therapy for Acute Treatment of Migraine
Read More
August 15, 2021
Theranica Announces the Establishment of a Unique Level II HCPCS Code by the Centers for Medicare and Medicaid Services (CMS)
Granting of the Code Follows Continued Successful Clinical Trials of Nerivio in Adolescent Patients as well as those with Menstrual Migraine
Read More
June 30, 2021
Study Compares Nerivio® to Standard Care Medications for Acute Treatment of Migraine in Adolescents
Peer-Reviewed Study Compares Treatment Results from Migraine Medications to Using Nerivio’s Remote Electrical Neuromodulation
Read More
June 21, 2021
Peer-Reviewed Study Suggests Nerivio® Effective for Treatment of Acute Menstrual Migraine Headache
20%-25% of women with migraine have menstrual migraine, which is typically associated with greater disability
Read More
March 2, 2021
Nerivio® Drug-free Wearable Surpasses 100,000 Migraine Treatments in the US
Nerivio Usage Grows Significantly Following Indication Expansion to Adolescents
Read More
February 16, 2021
Veterans Affairs (VA) Signs Agreement with Theranica to Make Nerivio® Acute Migraine Therapeutic Device Available to Veterans
Drug-Free Smartphone-Controlled Wearable Device Will Address Veteran Community, which has Higher Prevalence Migraine Compared to the General Population
Read More
January 25, 2021
FDA Approves Theranica’s Nerivio® for Acute Treatment of Migraine in Adolescents
The Prescribed Wearable Device is Now indicated for Patients 12 Years Old and Above
Read Article
October 26, 2020
Nerivio® Receives Clearance of Expanded Indication to Cover Chronic Migraine Patients
Clinical Evidence Supports Efficacy of Theranica’s Prescribed Digital Therapeutic in Adult Chronic Migraine Patients
Read More
September 17, 2020
Largescale Real-World Migraine Study Solidifies Efficacy And Safety of Theranica’s Nerivio® Device
Peer-Reviewed Post-Marketing Surveillance Study Tested Efficacy and Safety of Remote Electrical Neuromodulation (REN) in Acute Treatment of Migraine
Read More
September 8, 2020
Nerivio® Smartphone-Controlled Wearable for Acute Treatment of Migraine Granted CE Mark for Use in Europe
Theranica Announces Nerivio will be Available in Select European Countries Starting in 2021
Read More
July 16, 2020
KRAIBURG TPE supplies custom-colored medical-grade thermoplastic elastomer for Nerivio, an innovative drug-free neuromodulation therapeutic wearable from Theranica
Nerivio®, a novel wireless neuromodulation wearable from Theranica for drug-free acute treatment of migraine, features an electronic housing molded in a THERMOLAST® M custom-colored medical-grade thermoplastic elastomer compound from KRAIBURG TPE.
Read More
July 15, 2020
Theranica Reports Positive Study Results of Nerivio® for Chronic Migraine Patients
New Peer-Reviewed Article Publishes Results of Clinical Study Testing Efficacy of Remote Electrical Neuromodulation in Acute Treatment of Migraine in Chronic Migraine Patients
Read More
May 18, 2020
Theranica Expands Executive Team Amid Growing US Demand for Its FDA-authorized Migraine Treatment Wearable Device
During Initial Limited Commercial Launch, Nerivio® Was Used more than 30,000 Times to Address Migraine Pain and other Symptoms
Read More
April 6, 2020
Theranica Expands Access to Prescribed Migraine Wearable Nerivio™ Through Partnership With UpScript Health Telemedicine Platform
FDA-Authorized Drug-Free Migraine Treatment Device Available by Prescription through One-Stop Telemedicine Platform
Read More
March 10, 2020
Theranica Named to Fast Company’s Annual List of the World’s Most Innovative Companies for 2020
Developer of Nerivio™, a Drug-Free Therapeutic Wearable for the Acute Treatment of Migraine, Recognized as a Leading Biotech Innovator
Read More
February 25, 2020
Theranica Expands Accessibility of Nerivio™ to U.S. Migraine Patients Via Partnership With Telemedicine Platform, Cove
Cove Provides Rapid Consultation with a Licensed Physician and Home Delivery of the Novel FDA-Authorized Prescribed Wearable Device
Read More
December 18, 2019
Theranica Named 2020 ‘Game Changer’ by CB Insights
BioMed Tech Developer Included in “Electro-Charged Therapeutics” Category Recognizing Companies Creating a Drug-Free Future
Read More
December 3, 2019
Theranica: Journal of Expert Review of Medical Devices Publishes Profile of Nerivio
Review Highlights Efficacy and Safety of Smartphone-Controlled Prescribed Wearable for the Acute Treatment of Migraine
Read More
November 21, 2019
Theranica’s Nerivio™ Named in TIME’s List of 100 Best Inventions of 2019
Acute Migraine Smartphone-Controlled Prescription Wearable Recognized in Health Care Category
Read More
November 18, 2019
Theranica Announces U.S. Recycling Partnership in Commitment to Sustainable Medical Device Production
Partnership Advances Circular Economy by Making Nerivio™, a Prescribed Wearable for Acute Treatment of Migraine, Recyclable
Read More
July 23, 2019
New Publication Compares Remote Electrical Neuromodulation for Acute Treatment of Migraine to Treatment with Acute Medications
Headache Researchers in California and Missouri Conducted a Per-Patient Comparison of FDA-Cleared Wearable Device with Contemporary Usual Care
Read More
June 24, 2019
Theranica Appoints Senior Executives to Lead its New USA Subsidiary
New Executive Team Will Oversee US Commercialization of FDA-Cleared Nerivio™ for Acute Treatment of Migraine
Read More
May 28, 2019
FDA Grants Theranica De Novo to Market First Smartphone-Controlled Acute Migraine-Relief Wearable Device
Clinical Data Show 66.7% Pain Relief Response Within Two Hours
Read More
May 13, 2019
OMRON VENTURES Joins Theranica’s Series B Funding Round as Strategic Investor
Strategic investment signals positive response of healthcare community to Theranica’s new approach to migraine management
Read More
March 18, 2019
Theranica Raises $35M to Bring Innovative Migraine Device to the USA aMoon leads round B of financing of the Israel-based company
aMoon leads round B of financing of the Israel-based company
Read More
November 15, 2018
Theranica Announces Results from Pivotal Study of Device for Treating Acute Migraine
Results of largest study with a migraine device solidify safety, efficacy and tolerability of the drug-free Nerivio Migra, offering huge clinical benefit for migraineurs
Read More
July 03, 2017
Theranica Raises $6M to Combat Migraine
Lightspeed leads round A of financing in Israel-based advanced e-health company
Read More